I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.119 SGD 8.18% Market Closed
Market Cap: 113.8m SGD

Net Margin
IX Biopharma Ltd

-130.6%
Current
-175%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-130.6%
=
Net Income
-10.1m
/
Revenue
7.8m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SG
IX Biopharma Ltd
SGX:42C
105.7m SGD
-131%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
27%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
16%
CH
Novartis AG
SIX:NOVN
202.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
147B USD
16%
No Stocks Found

IX Biopharma Ltd
Glance View

Market Cap
105.7m SGD
Industry
Pharmaceuticals

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

42C Intrinsic Value
0.033 SGD
Overvaluation 72%
Intrinsic Value
Price
I
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-130.6%
=
Net Income
-10.1m
/
Revenue
7.8m
What is the Net Margin of IX Biopharma Ltd?

Based on IX Biopharma Ltd's most recent financial statements, the company has Net Margin of -130.6%.

Back to Top